- Home
- GIGM vs IMNN Comparison
GIGM vs IMNN Comparison
Compare GIGM & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | IMNN |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 11.0M |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GIGM | IMNN |
|---|---|---|
| Price | $1.51 | $3.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | 5.4K | ★ 16.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $0.37 |
| 52 Week High | $1.89 | $9.32 |
Technical Indicators
Market Signals| Indicator | GIGM | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 43.16 |
| Support Level | $1.49 | $3.03 |
| Resistance Level | $1.58 | $3.16 |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 61.11 | 20.63 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).